Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KCNH2 | Q12809 | 2/20 | 0.38 |
| ▸ | CSF1R | P07333 | 2/20 | 0.38 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.38 |
| ▸ | HDAC4 | P56524 | 1/20 | 0.38 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.38 |
| ▸ | HDAC7 | Q8WUI4 | 1/20 | 0.38 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.38 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.38 |
| ▸ | HDAC5 | Q9UQL6 | 1/20 | 0.38 |
| ▸ | HTT | P42858 | 1/20 | 0.38 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.37 |
| ▸ | PPARD | Q03181 | 1/20 | 0.37 |
| ▸ | EGLN2 | Q96KS0 | 1/20 | 0.37 |
| ▸ | EGLN1 | Q9GZT9 | 1/20 | 0.37 |
| ▸ | EGLN3 | Q9H6Z9 | 1/20 | 0.37 |
| ▸ | RAB9A | P51151 | 2/20 | 0.36 |
| ▸ | SCN9A | Q15858 | 1/20 | 0.36 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29685866 | 1.00 | KCNH2 (0.38) | KCNH2CSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL29685044 | 0.90 | CSF1R (0.36) | KCNH2CSF1REGLN2EGLN1EGLN3 | |
| SCHEMBL24468980 | 0.90 | CSF1R (0.36) | KCNH2CSF1REGLN2EGLN1EGLN3 | |
| SCHEMBL24468570 | 0.87 | KCNH2 (0.38) | KCNH2CSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL27181715 | 0.87 | MEN1 (0.49) | HDAC3HDAC4HDAC1HDAC7HDAC2 | |
| SCHEMBL29685414 | 0.84 | CSF1R (0.37) | KCNH2CSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL27181829 | 0.84 | CSF1R (0.37) | KCNH2CSF1RHDAC3HDAC4HDAC1 | |
| SCHEMBL24468617 | 0.82 | PRMT5 (0.49) | ROCK2PPARDSCN9AMEN1KMT2A | |
| SCHEMBL29685483 | 0.82 | PRMT5 (0.49) | ROCK2PPARDSCN9AMEN1KMT2A | |
| SCHEMBL29685468 | 0.82 | PRMT5 (0.49) | ROCK2PPARDSCN9AMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | claimed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | claimed |
| CN-116783191-A | Tricyclic carboxamide derivatives as PRMT5 inhibitors | 美国安进公司 | 2023-09-19 | — | — | CN | claimed |
| EP-4251624-B1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC (US) | 2025-10-29 | — | — | EP | disclosed |
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. | 2024-03-28 | — | — | US | disclosed |
| CN-116783191-A | Tricyclic carboxamide derivatives as PRMT5 inhibitors | 美国安进公司 | 2023-09-19 | — | — | CN | disclosed |
| WO-2022115377-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | AMGEN INC. (US) | 2022-06-02 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240101570-A1 | TRICYCLIC CARBOXAMIDE DERIVATIVES AS PRMT5 INHIBITORS | PRMT5, PRMT1, PRMT3 | KCNH2 4164/4885CSF1R 1126/4885HDAC3 24/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.